Gilead Wins Reversal of $1.2 Billion Bristol-Myers Decision (2)

Gilead Sciences Inc. persuaded a U.S. appeals court to reverse a $1.2 billion judgment Bristol-Myers Inc. had won over revolutionary treatments that use a body’s own immune system to fight cancer.

A patent owned by Bristol-Myers’s Juno Therapeutics and the Sloan Kettering Institute for Cancer Research is invalid, the U.S. Court of Appeals for the Federal Circuit ruled. The jury verdict that upheld the patent was “not supported by substantial evidence,” the three-judge panel ruled.

The fight was over a pioneering technique known as CAR-T, in which the T cells of a person’s own immune system are modified to ...